Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Revenue (2022 - 2025)

Oramed Pharmaceuticals' Revenue history spans 4 years, with the latest figure at $2.0 million for Q1 2025.

  • For Q1 2025, Revenue rose 437.84% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, changed N/A, while the annual FY2025 figure was $2.0 million, 334.47% up from the prior year.
  • Revenue reached $2.0 million in Q1 2025 per ORMP's latest filing, up from -$261000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.0 million in Q1 2025 to a low of -$592000.0 in Q1 2024.
  • Average Revenue over 4 years is $601444.4, with a median of $674000.0 recorded in 2022.
  • Peak YoY movement for Revenue: crashed 188.89% in 2024, then surged 437.84% in 2025.
  • A 4-year view of Revenue shows it stood at $904000.0 in 2022, then decreased by 25.44% to $674000.0 in 2023, then tumbled by 138.72% to -$261000.0 in 2024, then surged by 866.28% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Revenue are $2.0 million (Q1 2025), -$261000.0 (Q2 2024), and -$592000.0 (Q1 2024).